Compare Cassava Sciences Inc (FLNA) vs STMicroelectronics NV (STM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs STMicroelectronics NV — how do they compare? Cassava Sciences Inc trades at $0.97 (market cap $47.75M), while STMicroelectronics NV trades at $55.56 (market cap $49.31B). The key difference: STMicroelectronics NV is far larger — about 1032.7× Cassava Sciences Inc's market cap, and STMicroelectronics NV pays a 0.66% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | STM | |
|---|---|---|
Market Cap | $47.75M | $49.31B |
Sector | Health | Financials |
52-Week High | $4.64 | $79.91 |
52-Week Low | $0.87 | $21.20 |
Enterprise Value | -$34.93M | $47.30B |
Dividend Yield | — | 0.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.
Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.
STM trades at $56.10, up 5.29% with a bullish technical signal despite recent earnings misses. The stock shows mixed fundamentals with a high P/E of 110 but improving revenue outlook to $13.1B for 2026. Recent news highlights AI data center growth potential targeting $2B by 2027, though Q3 2026 revenue guidance missed estimates causing volatility.
Analyst consensus remains positive with $74.63 price target (51.72% buy ratings), but execution risks in AI expansion and margin pressure from Power & Discrete segments warrant caution. The stock offers growth exposure to semiconductor recovery with balanced risk-reward near current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About STMicroelectronics NV
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.
Read more on STM →
